Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.06
VSCI's Cash to Debt is ranked lower than
58% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. VSCI: 0.06 )
VSCI' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 0.06

Equity to Asset -1.34
VSCI's Equity to Asset is ranked lower than
59% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. VSCI: -1.34 )
VSCI' s 10-Year Equity to Asset Range
Min: -1.34   Max: 0.92
Current: -1.34

-1.34
0.92
F-Score: 4
Z-Score: -14.02
M-Score: -3.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -43.51
VSCI's Operating margin (%) is ranked higher than
50% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. VSCI: -43.51 )
VSCI' s 10-Year Operating margin (%) Range
Min: -158.06   Max: -16.27
Current: -43.51

-158.06
-16.27
Net-margin (%) -45.09
VSCI's Net-margin (%) is ranked higher than
51% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. VSCI: -45.09 )
VSCI' s 10-Year Net-margin (%) Range
Min: -151.61   Max: 212
Current: -45.09

-151.61
212
ROA (%) -71.21
VSCI's ROA (%) is ranked lower than
55% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. VSCI: -71.21 )
VSCI' s 10-Year ROA (%) Range
Min: -108.04   Max: 60.94
Current: -71.21

-108.04
60.94
ROC (Joel Greenblatt) (%) -110.94
VSCI's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. VSCI: -110.94 )
VSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -511.57   Max: -86.08
Current: -110.94

-511.57
-86.08
Revenue Growth (%) 9.70
VSCI's Revenue Growth (%) is ranked higher than
83% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. VSCI: 9.70 )
VSCI' s 10-Year Revenue Growth (%) Range
Min: -17.4   Max: 10.1
Current: 9.7

-17.4
10.1
EBITDA Growth (%) -18.80
VSCI's EBITDA Growth (%) is ranked higher than
62% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. VSCI: -18.80 )
VSCI' s 10-Year EBITDA Growth (%) Range
Min: -54   Max: 54.9
Current: -18.8

-54
54.9
EPS Growth (%) -18.10
VSCI's EPS Growth (%) is ranked higher than
64% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. VSCI: -18.10 )
VSCI' s 10-Year EPS Growth (%) Range
Min: -47.7   Max: 48.1
Current: -18.1

-47.7
48.1
» VSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

VSCI Guru Trades in Q2 2013

Jim Simons 87,500 sh (-8.85%)
» More
Q3 2013

VSCI Guru Trades in Q3 2013

Jim Simons 80,300 sh (-8.23%)
» More
Q4 2013

VSCI Guru Trades in Q4 2013

Jim Simons 70,000 sh (-12.83%)
» More
Q1 2014

VSCI Guru Trades in Q1 2014

Jim Simons 67,700 sh (-3.29%)
» More
» Details

Insider Trades

Latest Guru Trades with VSCI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 2.83
VSCI's P/S is ranked higher than
70% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. VSCI: 2.83 )
VSCI' s 10-Year P/S Range
Min: 2.14   Max: 21.25
Current: 2.83

2.14
21.25
EV-to-EBIT -9.87
VSCI's EV-to-EBIT is ranked lower than
55% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. VSCI: -9.87 )
VSCI' s 10-Year EV-to-EBIT Range
Min: 45.6   Max: 6267.8
Current: -9.87

45.6
6267.8
Current Ratio 3.42
VSCI's Current Ratio is ranked higher than
75% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. VSCI: 3.42 )
VSCI' s 10-Year Current Ratio Range
Min: 2.02   Max: 12.52
Current: 3.42

2.02
12.52
Quick Ratio 1.94
VSCI's Quick Ratio is ranked higher than
67% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. VSCI: 1.94 )
VSCI' s 10-Year Quick Ratio Range
Min: 1.36   Max: 11.71
Current: 1.94

1.36
11.71

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.50
VSCI's Price/Median PS Value is ranked higher than
96% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. VSCI: 0.50 )
VSCI' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 2.19
Current: 0.5

0.37
2.19
Forward Rate of Return (Yacktman) -34.54
VSCI's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. VSCI: -34.54 )
VSCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.4   Max: -1.1
Current: -34.54

-2.4
-1.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Vision-Sciences Inc. was incorporated in Delaware, and is the successor to operations originally begun in 1987. The Company and its subsidiaries designs, develops, manufactures and markets products for endoscopy, the science of using an instrument known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. The Company operates in two reportable segments: medical and industrial. Its medical segment designs, manufactures and sells its advanced line of endoscopy-based products, including its state-of-the-art flexible endoscopes and its Slide-On EndoSheath technology referred to as a sheath or EndoSheath disposable, for a variety of markets and specialties. Endoscopes are used in a number of specialties and sub-specialties, its flexible fiber and video endoscopes are currently designed for screening, diagnostic and therapeutic procedures in six primary fields: urology, pulmonology (critical care), surgery, GI, ENT, and spine. Its industrial segment, through its wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers for the visual inspection of narrow cavities. The Company's borescopes are used to inspect aircraft engines, casting parts and ground turbines, among other items. Its products are sold throughout the world through direct sales representatives in the United States, and independent distributors for the rest of the world. Its geographic markets are the U.S. and Europe. The Company owns the registered trademarks Vision Sciences, Slide-On, EndoSheath, and The Vision System. Its competitors are Olympus, GE Inspection Technologies, Karl Storz Industrial, Pentax, Karl Storz GmbH & Co. and Stryker Corp. The Company faces competition from companies such as Olympus, Pentax, and Karl Storz. The Company's operations are regulated under various federal, state, and local laws governing the environment, including laws governing the discharge of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the clean-up of contaminated sites.
» More Articles for VSCI

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 09 2011 
VisionSciences Inc. Reports Operating Results (10-Q) Nov 10 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Aug 11 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
VisionSciences Inc. Reports Operating Results (10-Q) Nov 12 2009 
VisionSciences Inc. Reports Operating Results (10-Q) Feb 13 2009 

More From Other Websites
Vision-Sciences to Host First Quarter Fiscal 2015 Results Call Jul 24 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Other Events Jul 08 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Jun 27 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jun 17 2014
VISION SCIENCES INC /DE/ Financials Jun 06 2014
VISION SCIENCES INC /DE/ Files SEC form 10-K, Annual Report May 30 2014
Vision-Sciences Introduces Next Generation, EndoSheath(R) Bronchoscopy System May 19 2014
Vision-Sciences' CEO Discusses F4Q 2014 Results - Earnings Call Transcript Apr 29 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2014
Vision-Sciences Announces Record Revenues of $5.0 Million for Fourth Quarter and $17.1 Million for... Apr 28 2014
Vision-Sciences to Discuss EndoSheath(R) Technology on "Taking Stock with Pimm Fox" Mar 17 2014
Vision-Sciences to Present at BTIG's Inaugural Snowbird Medical Technology and Diagnostics... Mar 13 2014
Patient Safety Awareness Week Brings Awareness to Health Care-Acquired Infection Mar 04 2014
VISION SCIENCES INC /DE/ Files SEC form 10-Q, Quarterly Report Feb 14 2014
Vision-Sciences' CEO Discusses F3Q 2014 Results - Earnings Call Transcript Feb 04 2014
Vision-Sciences Announces Revenue of $4.5 Million for Third Quarter and $12.1 Million for First Nine... Feb 03 2014
VISION SCIENCES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 03 2014
Vision-Sciences to Host Third Quarter Fiscal 2014 Results Call Jan 24 2014
Vision-Sciences' EndoSheath(R) Technology Offers Patented Solution to "Nightmare Bacteria" Jan 13 2014
Vision-Sciences Selected as Preferred Vendor for Endoscopy Equipment by 21st Century Oncology Dec 19 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide